Virus vectors and methods of making and administering the same
OwnerJoseph Rabinowitz, Richard Samulski +1inventors
InventorsJoseph Rabinowitz, Richard Samulski, Weidong Xiao
Life of this patent
Estimating the term…
Abstract
The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors.
Claims47
A hybrid virus particle comprising:
- a parvovirus capsid;
- and
- a nucleic acid comprising at least one adeno-associated virus (AAV) serotype 5 inverted terminal repeat packaged within said parvovirus capsid, subject to the proviso that said parvovirus capsid is not an AAV serotype 5 capsid.
A cell comprising a vector, the vector comprising:
- parvovirus cap genes,
- adeno-associated virus (AAV) rep genes, and
- a nucleic acid comprising at least one AAV inverted serotype 5 terminal repeat,
- subject to the proviso that said parvovirus cap genes are not AAV serotype 5 cap genes.
A cell comprising parvovirus cap genes and adeno-associated virus (AAV) rep genes stably integrated into the genome of the cell, subject to the proviso that if said parvovirus cap genes are not AAV serotype 2 cap genes, the serotypes of said AAV cap genes and said AAV rep genes are different.
A method of producing a hybrid virus particle, the method comprising:
- providing a cell with adeno-associated virus (AAV) rep genes, parvovirus cap genes, a nucleic acid comprising at least one AAV serotype 5 inverted terminal repeat, and helper functions for generating a productive AAV infection;
- subject to the proviso that the parvovirus cap genes are not AAV serotype 5 cap genes, and
- allowing assembly of the hybrid virus particles.
44-53. (canceled)
56-63. (canceled)
Dependencies are inferred from the claim text.